Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multi-Drug Regimen for Severe Pulmonary Fibrosis in HPS
NCT00467831Phase 2Terminated
- Sponsor
- National Human Genome Research Institute
- Start
- Apr 2007
- Primary completion
- Nov 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of losartan, zileuton extended release, acetylcysteine, pravastatin and erythromycin in Hermansky-Pudlak syndrome (HPS) and pulmonary fibrosis (PF), sponsored by National Human Genome Research Institute. Primary endpoint: Survival at 2 Years. Started Apr 2007; status: terminated.
02
Drugs
losartanzileuton extended releaseacetylcysteinepravastatinerythromycin
03
Conditions
Hermansky-Pudlak syndrome (HPS)pulmonary fibrosis (PF)
Beyond the preview
Go deeper on NCT00467831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00467831.